TherapeuticsMD (NASDAQ:TXMD) Stock Price Passes Below 50-Day Moving Average – Here’s Why

Posted by Stanley Muller on Aug 21st, 2026

TherapeuticsMD, Inc. (NASDAQ:TXMD – Get Free Report) passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $2.06 and traded as low as $2.01. TherapeuticsMD shares last traded at $2.06, with a volume of 25,510 shares.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of TherapeuticsMD from a “sell (d-)” rating to a “sell (d+)” rating in a research report on Wednesday, August 12th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

View Our Latest Analysis on TXMD

TherapeuticsMD Stock Performance

The company has a market cap of $23.83 million, a PE ratio of 103.00 and a beta of 0.61. The company’s 50 day moving average price is $2.06 and its 200-day moving average price is $2.12.

TherapeuticsMD (NASDAQ:TXMD – Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($6.12) by $6.13. TherapeuticsMD had a negative return on equity of 1.09% and a negative net margin of 6.64%.The business had revenue of $0.87 million for the quarter, compared to the consensus estimate of $19.77 million.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Citadel Advisors LLC grew its stake in shares of TherapeuticsMD by 125.5% during the 3rd quarter. Citadel Advisors LLC now owns 34,273 shares of the company’s stock worth $36,000 after acquiring an additional 19,073 shares during the period. Renaissance Technologies LLC raised its stake in TherapeuticsMD by 171.8% in the 4th quarter. Renaissance Technologies LLC now owns 96,500 shares of the company’s stock valued at $157,000 after acquiring an additional 61,000 shares during the period. Finally, Tejara Capital Ltd lifted its holdings in TherapeuticsMD by 1.9% during the fourth quarter. Tejara Capital Ltd now owns 350,852 shares of the company’s stock valued at $572,000 after purchasing an additional 6,649 shares during the last quarter. Hedge funds and other institutional investors own 30.74% of the company’s stock.

About TherapeuticsMD

(Get Free Report)

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.